A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Clinical trial NCT06635954 · RECRUITING

Trial details

NCT number: NCT06635954
Sponsor: Oxford Biodynamics Inc.
Status: RECRUITING
Study type: OBSERVATIONAL

Cancer Immunotherapy PD-1 PD-L1 Immune Checkpoint Therapy

Start date: 2024-05-14
Primary completion: 2026-05-14
Enrollment: 2000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.